GlassScriptPhysician profile
Thomas James Smitherman
NPI 1750484804
$2,003.44
in general payments reported to CMS, 2019-2025
22 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $870 · 2021: $428 · 2022: $706.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $293.73 | 2019-2022 | |
| Astrazeneca Pharmaceuticals LP | $247.25 | 2019-2022 | |
| Abbvie INC. | $192.18 | 2021-2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $140.22 | 2021-2022 | |
| Lilly USA, LLC | $130.37 | 2021-2022 | |
| Amgen INC. | $122.34 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $112.22 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $99.76 | 2019-2022 | |
| Amarin Pharma, INC. | $93.48 | 2019-2021 | |
| Pfizer INC. | $89.37 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $76.38 | 2019-2022 | |
| Janssen Pharmaceuticals, INC | $73.70 | 2019-2021 | |
| Melinta Therapeutics, LLC | $60.49 | 2019 | |
| Vanda Pharmaceuticals INC. | $53.28 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $50.06 | 2019-2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Biohaven Pharmaceutical Holding Company LTD. | $39.18 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $38.82 | 2019-2021 | |
| Glaxosmithkline, LLC. | $32.98 | 2022 | |
| Supernus Pharmaceuticals, INC. | $18.71 | 2022 | |
| Biogen, INC. | $14.26 | 2021 | |
| Allergan, INC. | $12.52 | 2019 | |
| Eisai INC. | $12.14 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Smitherman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.